Latest Conference Articles

Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer

Adjuvant nivolumab extended DFS, NUTRFS, and DMFS vs placebo and showed for the first time an improvement in OS in patients with high-risk muscle-invasive urothelial cancer.

Simulations Improve CAR T-Cell Therapy Understanding and Administration Confidence

Simulation-based education can improve health care professionals’ understanding and confidence regarding the treatment of patients with CAR T-cell therapy.

Orca-T May Be a Suitable Option Over PTCy-Based HSCT in Acute Leukemia and MDS

Orca-T demonstrated positive impacts on relapse-free survival and overall survival vs PTCy-based HSCT in acute leukemias and myelodysplastic syndrome.

Orca-T Proves Safe and Effective in Advanced Hematologic Malignancies

The regulatory T cell enriched donor cell agent Orca-T was safe and displayed activity in the reduced intensity conditioning setting for patients with advanced hematologic malignancies.

Nadofaragene Firadenovec Showcases Sustained Responses in BCG-Unresponsive NMIBC

The intravesical gene therapy elicited durable remissions in a high percentage of patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer.

Insider Insights: Unveiling Takeaways from AACR 2024

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.

Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

Savolitinib/Osimertinib Yields Responses in EGFR-Mutant, MET-Amplified, Osimertinib-Resistant NSCLC

Responses with savolitinib plus osimertinib were higher in patients with NSCLC who had higher MET amplification cutoffs vs the overall population.

Novel CAR T-Cell Therapy HR001 Demonstrates Efficacy in R/R Non-Hodgkin Lymphoma

The novel CAR T-cell agent HR001 was effective, with durable responses and a favorable safety profile observed, in relapsed/refractory non-Hodgkin lymphoma.

RGI-2001 Plus Tacrolimus/Methotrexate Demonstrates Protective Effect From Acute GVHD Post Allo-HSCT

Prophylactic treatment with RGI-2001 plus tacrolimus and methotrexate led to a lower incidence of acute GVHD vs CIBMTR control following allo-HSCT.

PSMA-Directed Targeted Alpha Therapy Shows Activity in Heavily Pretreated Metastatic CRPC

FPI-2265 showed promising activity in patients with metastatic castration-resistant prostate cancer which was similar to prior safety and efficacy data reported.

Dr Jänne on an Exploratory Analysis from FLAURA2 of Baseline ctDNA in EGFR+ NSCLC

Proteogenomic Signatures Shed Light on Prostate Cancer Recurrence Risk in Select Ancestries

A proteomics analysis revealed significant variations in protein expression and informative markers between African vs European prostate tumors.

Dr Christenson on Copanlisib Plus Nivolumab in Pretreated PIK3Ca+ MSS mCRC

Eric S. Christenson, MD, discusses efficacy data for copanlisib plus nivolumab in patients with pretreated, MSS metastatic colorectal cancer.

Investigational Vaccine TG4050 Shows Early Clinical Benefit in HPV– Head and Neck Cancers

Phase 1 data of TG4050 elicited tumor-specific immune responses that resulted in low relapse rates in patients with resected HPV–negative head and neck cancers.

AZD1390 Demonstrates Initial Safety, May Enhance Radiotherapy Efficacy in Glioblastoma

Early safety and efficacy data seen with AZD1390 in a phase 1 study indicate it's potential utility as a radiosensitizing treatment in glioblastoma.

Mirvetuximab Soravtansine Plus Pembrolizumab Makes a Splash in pMMR/MSS FRalpha+ Endometrial Cancer

Mirvetuximab soravtansine plus pembrolizumab displays efficacy in recurrent or persistent, FRalpha-positive, pMMR/MSS serous endometrial cancer.

Dr Srour on the Safety and Efficacy of the Allogeneic CAR T-Cell Therapy CTX130 in Advanced ccRCC

Samer A. Srour, MB ChB, MS, discusses efficacy and safety data for the allogeneic CAR T-cell therapy CTX130 in advanced clear cell renal cell carcinoma.

Olaparib With Chemotherapy Does Not Elicit Improved Outcomes vs Chemotherapy Alone in BRCA Wild-Type TNBC

Olaparib on a gap schedule with chemotherapy does not improve responses vs chemotherapy alone in the neoadjuvant setting for patients with BRCA wild-type TNBC.

Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer

Rebecca L. Porter, MD, PhD, discusses the evaluation of mirvetuximab soravtansine plus pembrolizumab in FRα-positive, pMMR/MSS endometrial cancer.

Copanlisib Plus Nivolumab Demonstrates Activity in Microsatellite Stable Colorectal Cancer

Copanlisib plus nivolumab was active and met the primary end point of a phase 1/2 study in a cohort of patients with MSS CRC.

Exosome-Based Assay Shows Diagnostic Sensitivity, Specificity in Pancreatic Cancer

A microRNA assay combined with CA19-9 displayed diagnostic accuracy in the early detection of pancreatic cancer.

Saruparib Generates Early Efficacy and Safety Signals in HRR-Mutant Advanced Breast Cancer

Saruparib's favorable activity and safety may allow patients with advanced solid tumors to stay on treatment longer vs other approved PARP inhibitors.

Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC

Adagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.

Atezolizumab Fails to Improve Survival Outcomes After Definitive Local Therapy in High-Risk HNSCC

Administration of atezolizumab after definitive local therapy did not improve EFS or OS in patients with head and neck squamous cell carcinoma.

Linvoseltamab Elicits Deep Responses in Late-Stage R/R Multiple Myeloma

Linvoseltamab elicited responses with acceptable safety in patients with relapsed/refractory multiple myeloma, including difficult-to-treat subsets

CTX130 Provides Disease Control and Manageable Safety in Advanced ccRCC

The anti-CD70 CAR T-cell therapy CTX130 showed activity and manageable toxicities in advanced renal cell carcinoma.

Dr Wong on Atezolizumab After Definitive Local Therapy in High-Risk HNSCC

Deborah J. Wong, MD, PhD, discusses the evaluation of atezolizumab vs placebo after definitive local therapy in high-risk, locally advanced HNSCC.

Dr Migden on RP1 in Advanced Cutaneous Malignancies After Solid Organ Transplant

Michael R. Migden, MD, discusses efficacy data for RP1 in advanced non-melanoma skin cancer after prior solid organ transplant.

In 5-Year Span of FDA Accelerated Approvals in Cancer, 43% Show Confirmatory Clinical Benefit

Fifty-seven percent of drugs granted accelerated approval for a cancer indication failed to show clinical benefit in confirmatory studies.